2020
DOI: 10.3389/fcimb.2020.00325
|View full text |Cite
|
Sign up to set email alerts
|

HCV Replicon Systems: Workhorses of Drug Discovery and Resistance

Abstract: The development of direct-acting antivirals (DAAs) has revolutionized the state-of-the art treatment of HCV infections, with sustained virologic response rates above 90%. However, viral variants harboring substitutions referred to as resistance-associated substitutions (RASs) may be present in baseline levels and confer resistance to DAAs, thereby posing a major challenge for HCV treatment. HCV replicons have been the primary tools for discovering and evaluating the inhibitory activity of DAAs against viral re… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
13
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 16 publications
(13 citation statements)
references
References 136 publications
0
13
0
Order By: Relevance
“…While the use of replicon DNA to transfect BHK-21 cells streamlines the workflow relative to the use of transcribed RNA, the workflow can be simplified further through the use stable replicon harboring cell lines; similar tools have proven extremely beneficial in drug development for HCV (58,59). Surprisingly, while a stable replicon harboring cell line was generated for SARS-CoV (60), none of the published SARS-CoV-2 replicon systems have led to the production of stable replicon harboring cell lines.…”
Section: Generation Of Sars-cov-2 Replicon-expressing Cell Linesmentioning
confidence: 99%
“…While the use of replicon DNA to transfect BHK-21 cells streamlines the workflow relative to the use of transcribed RNA, the workflow can be simplified further through the use stable replicon harboring cell lines; similar tools have proven extremely beneficial in drug development for HCV (58,59). Surprisingly, while a stable replicon harboring cell line was generated for SARS-CoV (60), none of the published SARS-CoV-2 replicon systems have led to the production of stable replicon harboring cell lines.…”
Section: Generation Of Sars-cov-2 Replicon-expressing Cell Linesmentioning
confidence: 99%
“…However, stable cell lines harboring EV71 SGR were not successful in our hands even with EMCV IRES to enhance viral RNA replication, suggesting some adaptive mutations are required for efficient replication. Indeed, stable cell lines harboring SGR are successful only in several viruses, mainly in the flaviviridae family, like Hepatitis C virus ( Lohmann et al, 1999 ; Bartenschlager, 2002 ), Dengue virus ( Ng et al, 2007 ), etc., and most of them are associated with adaptive mutations ( Bartenschlager, 2002 ; Khan et al, 2020 ).…”
Section: Discussionmentioning
confidence: 99%
“…Drug discovery and resistance studies on HCV become more and more important in the era of DAAs. The HCV replicon systems have become indispensable in the development of effective DAAs and the investigation of drug resistance (24), requiring a large number of infectious particles for high throughput anti-viral library assessments. These two new purification methods of HCV particles have shown potential application in this field.…”
Section: Discussionmentioning
confidence: 99%